Indaptus Therapeutics, Inc. (INDP)

Indaptus Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	8.53	8.76	8.59	5.21	0.94	8.29
Research & Development	7.33	7.62	6.32	2.52	2.66	26.66
Other Operating Expenses	0	0	0	0	0	12.16
Operating Expenses	15.87	16.38	14.91	7.73	3.6	47.11
Operating Income	-15.87	-16.38	-14.91	-7.73	-3.6	-47.11
Interest Expense / Income	0	0	0	0	0	-0.15
Other Expense / Income	-0.89	-0.96	-0.59	-0.02	-0.02	-
Pretax Income	-14.98	-15.42	-14.32	-7.71	-3.58	-46.96
Income Tax	0	0	0	0	0	0.64
Net Income	-14.98	-15.42	-14.32	-7.71	-3.58	-47.6
Shares Outstanding (Basic)	8	8	8	4	2	0
Shares Outstanding (Diluted)	8	8	8	4	2	0
Shares Change	0.49%	1.68%	101.98%	110.35%	360.55%	8.29%
EPS (Basic)	-1.78	-1.83	-1.73	-1.89	-1.84	-112.72
EPS (Diluted)	-1.78	-1.83	-1.73	-1.89	-1.84	-112.72
Free Cash Flow	-12.38	-13.41	-12.91	-10.84	-3.32	-29.97
Free Cash Flow Per Share	-1.47	-1.60	-1.56	-2.65	-1.71	-70.97
EBITDA	-14.98	-15.42	-14.32	-7.71	-3.58	-46.26
Depreciation & Amortization	0	0	0	0	0	0.85
EBIT	-14.98	-15.42	-14.32	-7.71	-3.58	-47.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).